Pfizer Corporation

Novartis International Pharmaceutical, Ltd.

Peter James Dunn

Albert Shaw Wood

Trevor Jack Newbury

Catherine Dunne

Garry O'Connor

John George Matthews

Philip Charles Levett

Michael John Humphrey

Paul Quinn

Michael Leslie Hughes

Garry O'connor

Garry O`Connor

Garry O'OCONNOR

A stable solid hydrate of a muscarinic receptor antagonist is useful in the treatment of irritable bowel syndrome, diverticular disease, oesophageal achalasia, chronic obstructive airways disease, over active bladder (including symptoms of incontinence, urge and frequency), urinary incontinence, neurogenic urinary urgency or pollakiuria, treatment of bladder functional disorder, urinary leakage, painful or difficult urination caused by neurogenic bladder, spastic or hypertonic bladder, dysfunctional bladder syndrome, gastrointestinal disorders including gastrointestinal hyperactivity, and relaxing effect on intestinal smooth muscle cells.

Stable hydrate of a muscarinic receptor antagonist

There is provided a process for the production a compound of general formula I:wherein A, R, R, Rand Rhave meanings given in the description, which process comprises the reaction of a compound of formula II,wherein Ris a group substitutable by an aminopyrazole, with a compound of general formula III

Process for the preparation of pyrazolopyrimidinones

The present invention is directed to a a method for the treatment of irritable bowel syndrome comprising the multiple daily pulse dosing of an immediate release formulation of the anti-muscarinic darifenacin. Dosing two or three times a day is particularly preferred.

Method of treating irritable bowel syndrome

A process is provided for the preparation of a compound of formulae (IA) (sidenafil) and (IB)

Process for preparation of pyrazolo&lsqb;4,3-d&rsqb;pyrimidin-7-ones and intermediates thereof

The present invention relates to a crystalline, &agr;-polymorphic form of a compound of formula (I) and to processes for the preparation of, to intermediates used in the preparation of, to compositions containing and to uses of, the &agr;-polymorphic form.

Crystalline polymorphic form of (S,S,S)-N-(1-&lsqb;2-carboxy-3 (N2-mesyllyslamino) propyl&rsqb;-1- cyclopentylcarbonyl) tyrosine

A process for the preparation of a compound of formula (I): ##STR1## which comprises cyclization of a compound of formula (II): ##STR2##

Growing community of inventors

Sandwich, United Kingdom

Peter James Dunn